Stock photo. 

Missouri juries have awarded $127 million in state talc-cancer cases this year, with more potentially to come, while New Jersey, a hotbed of talc-cancer litigation itself, recently threw out two similar cases. Why the disparity? According to a legal expert interviewed in a recent Forbes article, it may be fundamental differences in expert witness admissibility.

Litigation over the cancer risks of Johnson & Johnson’s talc powder products is heating back up after juries delivered two historic multi-million verdicts earlier this year, with trials slated for September in Missouri and October in New Jersey. Courtroom View Network hopes to webcast both trials, and as a lead up we are featuring a guest column by Dr. David Schwartz, Ph.D. of Innovative Science Solutions, breaking down some of the key scientific studies and expert testimony backing up the legal arguments in these high-stakes cases. (Become a CVN subscriber to watch previously recorded and upcoming talcum powder trials for as little as $99/month)